Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.

Sandhöfer, N

Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. [electronic resource] - Leukemia Apr 2015 - 828-38 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1476-5551

10.1038/leu.2014.305 doi


Animals
Antineoplastic Agents--pharmacology
Apoptosis--drug effects
Drug Synergism
Gene Expression Regulation, Leukemic
Gene Rearrangement
Heterocyclic Compounds, 3-Ring--pharmacology
Humans
Imidazoles--pharmacology
Leukemia, Myeloid, Acute--drug therapy
Mice
Myeloid-Lymphoid Leukemia Protein--genetics
Oncogene Proteins, Fusion--genetics
Phosphatidylinositol 3-Kinases--genetics
Phosphoinositide-3 Kinase Inhibitors
Proto-Oncogene Proteins c-akt--antagonists & inhibitors
Quinolines--pharmacology
Signal Transduction
Sirolimus--pharmacology
Survival Analysis
TOR Serine-Threonine Kinases--antagonists & inhibitors
Tumor Burden--drug effects
Xenograft Model Antitumor Assays